Table 2

Cost inputs

ParameterCost (€)Source
Active cancer treatment
 Weighted average monthly cost of treatment
  First-line
   HER2−/HR+1184 € 13 15–20
   HER2+/HR+7404 €
   HER2+/HR−7491 €
   Triple negative2823 €
  Second-line
   HER2−/HR+1670 € 13 15–20
   HER2+/HR+6869 €
   HER2+/HR−6656 €
   Triple negative1534 €
  Third-line
   HER2−/HR+1967 € 13 15–20
   HER2+/HR+6534 €
   HER2+/HR−6349 €
   Triple negative1609 €
Treatment of bone metastases
 Weighted average monthly cost of bone metastasis treatment316 € 13 15–20
Toxicity management
 Per-event toxicity management cost
  Neutropaenia546 € 13 15–20
  Febrile neutropaenia1875 €
  Leucopaenia390 €
  Lymphopaenia79 €
  Thrombocytopaenia1295 €
  Infection993 €
  Anaemia1794 €
  Haemorrhage3233 €
  All neuropathies644 €
  Nausea362 €
  Vomiting592 €
  Diarrhoea931 €
  Dehydration955 €
  Pain1255 €
  Hypersensitivity366 €
  Stomatitis/mucositis968 €
  Alopecia95 €
  Hepatobiliary – alanine aminotransferase358 €
  Hepatobiliary – aspartate aminotransferase358 €
  Hyperbilirubinaemia602 €
  Increased alkaline phosphatase200 €
  Hypertension417 €
  Dyspnea1241 €
  Fatigue895 €
  Skin reaction241 €
  Fluid retention687 €
  Hand and foot syndrome270 €
  Asthaenia953 €
Diagnosis
 One-time cost of diagnosis1191 € 13 15–20
Medical follow-up during active treatment
 Monthly cost of outpatient care during active treatment436 € 13 15–20
 Monthly cost of hospitalisations during active treatment635 €
Palliative/best supportive care
 One-time cost of medications during palliative/best supportive care391 € 13 15–20
 Monthly cost of medications during palliative/best supportive care2656 €
 Monthly cost of outpatient care during palliative/best supportive care330 €
 Monthly cost of hospitalisations during palliative/best supportive care1668 €
 Monthly cost of community/social services during palliative/best supportive care602 €
Indirect costs
 Monthly lost income8 € 1 21
  • HER2, human epidermal growth factor receptor 2; HR, hormonal receptor.